Skip to main content
REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.38
+1.73 (20.00%)
At close: Mar 9, 2026, 4:00 PM EDT
9.98
-0.40 (-3.85%)
After-hours: Mar 9, 2026, 7:57 PM EDT

REGENXBIO Revenue

In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth. REGENXBIO had revenue of $30.34M in the quarter ending December 31, 2025, with 43.00% growth.

Revenue (ttm)
$170.44M
Revenue Growth
+104.54%
P/S Ratio
3.14
Revenue / Employee
$459,410
Employees
371
Market Cap
535.74M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025170.44M87.11M104.54%
Dec 31, 202483.33M-6.91M-7.66%
Dec 31, 202390.24M-22.48M-19.94%
Dec 31, 2022112.72M-357.62M-76.03%
Dec 31, 2021470.35M315.78M204.30%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Vanda Pharmaceuticals 216.11M
Century Therapeutics 113.34M
Assembly Biosciences 37.19M
Entrada Therapeutics 25.42M
Lineage Cell Therapeutics 14.56M
4D Molecular Therapeutics 120.00K
Altimmune 41.00K
vTv Therapeutics 17.00K
Revenue Rankings

RGNX News

More News